Diagnostic imaging in the preoperative management of lung cancer
详细信息 查看全文
- 作者：Kazuhiro Imai (1)
Yoshihiro Minamiya (1)
Hajime Saito (1)
Satoru Motoyama (1)
Yusuke Sato (1)
Aki Ito (1)
Kei Yoshino (1)
Satoshi Kudo (1)
Shinogu Takashima (1)
Yasushi Kawaharada (1)
Nobuyasu Kurihara (1)
Kimito Orino (1)
Jun-ichi Ogawa (1) - 关键词：Lung cancer ; Preoperative management ; Computed tomography ; Magnetic resonance imaging ; Positron emission tomography
- 刊名：Surgery Today
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：44
- 期：7
- 页码：1197-1206
- 全文大小：
- 参考文献：1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74鈥?08. CrossRef
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69鈥?0. CrossRef
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710鈥?. CrossRef
4. Fukui T, Mitsudomi T. Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment. Surg Today. 2010;40:191鈥?. CrossRef
5. Sawabata N, Fujii Y, Asamura H, Nomori H, Nakanishi Y, Eguchi K, et al. Lung Cancer in Japan: analysis of Lung Cancer Registry for resected cases in 2004 (in Japanese). Jpn J Lung Cancer. 2010;50:875鈥?8. CrossRef
6. Downey RJ. Follow-up of patients with completely resected lung cancer. Chest. 1999;115:1487鈥?8. CrossRef
7. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg. 1994;8:37鈥?2. CrossRef
8. Van Schil P. The restaging issue. Lung Cancer. 2003;42(Suppl 1):S39鈥?5. CrossRef
9. Ueda K, Kaneda Y, Saeki K, Fujita N, Zempo N, Esato K. Hilar lymph nodes in N2 disease: survival analysis of patients with non-small cell lung cancers and regional lymph node metastasis. Surg Today. 2002;32:300鈥?. CrossRef
10. Marra A, Hillejan L, Zaboura G, Fujimoto T, Greschuchna D, Stamatis G. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg. 2003;125:543鈥?3. CrossRef
11. Fujimoto T, Cassivi SD, Yang P, Barnes SA, Nichols FC, Deschamps C, et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg. 2006;132:499鈥?06. CrossRef
12. Miyoshi K, Mimura T, Iwanaga K, Adachi S, Tsubota N, Okada M. Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today. 2010;40:428鈥?2. CrossRef
13. Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012;81:988鈥?001. CrossRef
14. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178鈥?01. CrossRef
15. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. American College of Chest Physicians. Invasive mediastinal staging of lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:202鈥?0. CrossRef
16. Akiba T, Marushima H, Harada J, Kobayashi S, Morikawa T. Importance of preoperative imaging with 64-row three-dimensional multidetector computed tomography for safer video-assisted thoracic surgery in lung cancer. Surg Today. 2009;39:844鈥?. CrossRef
17. McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung: therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836鈥?1.
18. Grillo HC. Technical considerations in stage III disease: pleural and chest wall involvement. In: Delarue NC, Eschapasse H, editors. International trends in general thoracic surgery, vol. 1st. Philadelphia: WB Saunders; 1985. p. 134鈥?.
19. Komaki R, Mountain CF, Holbert JM, Garden AS, Shallenberger R, Cox JD, et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys. 1990;19:31鈥?. CrossRef
20. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIa disease. Chest. 1990;97:1045鈥?1. CrossRef
21. Kawaguchi K, Mori S, Usami N, Fukui T, Mitsudomi T, Yokoi K. Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. Lung Cancer. 2009;64:41鈥?. CrossRef
22. Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
23. Travis WD, Brambilla E, Rami-Porta R, Valli猫res E, Tsuboi M, Rusch V, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1384鈥?0. CrossRef
24. Grenier P, Dubary B, Carette MF, Frija G, Musset D, Chastang C. Preoperative thoracic staging of lung cancer: CT and MR evaluation. Diagn Interv Radiol. 1989;1:23鈥?.
25. Uhrmeister P, Allmann KH, Wertzel H, Altehoefer C, Laubenberger J, Hasse J, et al. Chest wall infiltration by lung cancer: value of thin-sectional CT with different reconstruction algorithms. Eur Radiol. 1999;9:1304鈥?. CrossRef
26. Higashino T, Ohno Y, Takenaka D, Watanabe H, Nogami M, Ohbayashi C, et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56:48鈥?5. CrossRef
27. Imai K, Minamiya Y, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. Use of CT to evaluate pleural invasion in non-small cell lung cancer: measurement of the ratio of the interface between tumor and neighboring structures to maximum tumor diameter. Radiology. 2013;267(2):619鈥?6.
28. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29:26鈥?. CrossRef
29. Staples CA, M眉ller NL, Miller RR, Evans KG, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988;167:367鈥?2.
30. Lewis JW Jr, Pearlberg JL, Beute GH, Alpern M, Kvale PA, Gross BH, et al. Can computed tomography of the chest stage lung cancer? Yes and no. Ann Thorac Surg. 1990;49:591鈥?. CrossRef
31. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol. 1985;144:261鈥?. CrossRef
32. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990;141:1096鈥?01. CrossRef
33. Kramer H, Groen HJ. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg. 2003;238:180鈥?.
34. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s鈥攎eta-analytic comparison of PET and CT. Radiology. 1999;213:530鈥?. CrossRef
35. Imai K, Minamiya Y, Saito H, Nakagawa T, Hosono Y, Nanjo H, et al. Accuracy of helical computed tomography for the identification of lymph node metastasis in resectable non-small cell lung cancer. Surg Today. 2008;38:1083鈥?0. CrossRef
36. Ohno Y, Hatabu H, Takenaka D, Higashino T, Watanabe H, Ohbayashi C, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231:872鈥?. CrossRef
37. Hochhegger B, Marchiori E, Sedlaczek O, Irion K, Heussel CP, Ley S, et al. MRI in lung cancer: a pictorial essay. Br J Radiol. 2011;84:661鈥?. CrossRef
38. Sakai S, Murayama S, Murakami J, Hashiguchi N, Masuda K. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. J Comput Assist Tomogr. 1997;21:595鈥?00. CrossRef
39. Biederer J. General requirements of MRI of the lung and suggested standard protocols. In: Kauczor HU, editor. MRI of the lung. Berlin: Springer; 2009. p. 3鈥?6. CrossRef
40. Koyama H, Ohno Y, Kono A, Takenaka D, Maniwa Y, Nishimura Y, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18:2120鈥?1. CrossRef
41. Ohno Y, Koyama H, Dinkel J, Hintze C. Lung cancer. In: Kauczor HU, editor. MRI of the lung. Berlin: Springer; 2009. p. 179鈥?16. CrossRef
42. Ohno Y, Adachi S, Motoyama A, Kusumoto M, Hatabu H, Sugimura K, et al. Multiphase ECG triggered 3D contrast enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13:215鈥?4. CrossRef
43. Kajiwara N, Akata S, Uchida O, Usuda J, Ohira T, Kawate N, et al. Cine MRI enables better therapeutic planning than CT in cases of possible lung cancer chest wall invasion. Lung Cancer. 2010;69:203鈥?. CrossRef
44. Akata S, Kajiwara N, Park J, Yoshimura M, Kakizaki D, Abe K, et al. Evaluation of chest wall invasion by lung cancer using respiratory dynamic MRI. J Med Imaging Radiat Oncol. 2008;52:36鈥?. CrossRef
45. Shiotani S, Sugimura K, Sugihara M, Kawamitsu H, Yamauchi M, Yoshida M, et al. Diagnosis of chest wall invasion by lung cancer: useful criteria for exclusion of the possibility of chest wall invasion with MR imaging. Radiat Med. 2000;18:283鈥?0.
46. Heelan RT, Demas BE, Caravelli JF, Martini N, Bains MS, McCormack PM, et al. Superior sulcus tumors: CT and MR imaging. Radiology. 1989;170:637鈥?1.
47. Pitz CC, de la Rivi猫re AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM. Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg. 2004;26:202鈥?. CrossRef
48. Wittenberg KH, Adkins MC. MR imaging of nontraumatic brachial plexopathies: frequency and spectrum of findings. Radiographics. 2000;20:1023鈥?2. CrossRef
49. Fujimoto K, Edamitsu O, Meno S, Abe T, Honda N, Ogoh Y, et al. MR diagnosis for metastasis or non-metastasis of mediastinal and hilar lymph nodes in cases of primary lung cancer: detectability, signal intensity, and MR-pathologic correlation (in Japanese). Nihon Igaku Hoshasen Gakkai Zasshi. 1995;55:162鈥?1.
50. Takenaka D, Ohno Y, Hatabu H, Ohbayashi C, Yoshimura M, Ohkita Y, et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. Eur J Radiol. 2002;44:216鈥?4. CrossRef
51. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071鈥?0. CrossRef
52. Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer. 2008;60:62鈥?. CrossRef
53. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632鈥?2. CrossRef
54. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET鈥揅T, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007鈥?5. CrossRef
55. DiPerna CA, Wood DE. Surgical management of T3 and T4 lung cancer. Clin Cancer Res. 2005;11:5038鈥?4. CrossRef
56. Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. Biomed Biotechnol. 2012;2012:783739.
57. Takenaka T, Yano T, Morodomi Y, Ito K, Miura N, Kawano D, et al. Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography. Surg Today. 2012;42:934鈥?. CrossRef
58. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500鈥?. CrossRef
59. Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770鈥?. CrossRef
60. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, et al. Comparison of l -type amino acid transporter 1 expression and l -[3-18F]-伪-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 2010;37:911鈥?. CrossRef
61. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18 F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep. 2001;8:337鈥?.
62. Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47鈥?2. CrossRef
63. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET鈥揅T in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23鈥?2. CrossRef
64. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261鈥?. CrossRef
65. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255鈥?0. CrossRef
66. Behzadi A, Ung Y, Lowe V, Deschamps C. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg. 2009;52:235鈥?2.
67. Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6:1350鈥?. CrossRef
68. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008;246:772鈥?2. CrossRef
69. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245鈥?. CrossRef
70. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918鈥?4. CrossRef
71. Toaff JS, Metser U, Gottfried M, Gur O, Deeb ME, Lievshitz G, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography鈥揷omputed tomography. Invest Radiol. 2005;40:204鈥?. CrossRef
72. Duysinx BC, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun. 2006;27:971鈥?. CrossRef
73. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011鈥?. CrossRef
74. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (1聽cm), intermediate (1 to 3聽cm), and large (3聽cm) lymph node lesions. Chest. 2000;117:773鈥?. CrossRef
75. Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009;64:757鈥?2. CrossRef
76. Zhang R, Ying K, Shi L, Zhang L, Zhou L. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis. Eur J Cancer. 2013;49(8):1860鈥?.
77. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging. 2002;29:804鈥?. CrossRef
78. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician鈥檚 perspective. J Nucl Med. 2002;43:752鈥?.
79. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:1357鈥?0. CrossRef
80. Guly谩s B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173鈥?0.
81. Aquino SL, Asmuth JC, Alpert NM, Halpern EF, Fischman AJ. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-d -glucose-positron emission tomography and computed tomography registration. J Comput Assist Tomogr. 2003;27:479鈥?4. CrossRef
82. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-d -glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest. 2004;125:1413鈥?3. CrossRef
83. Pozo-Rodr铆guez F, Mart铆n de Nicol谩s JL, S谩nchez-Nistal MA, Maldonado A, Garc铆a de Barajas S, Calero-Garc铆a R, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23:8348鈥?6. CrossRef - 作者单位：Kazuhiro Imai (1)
Yoshihiro Minamiya (1)
Hajime Saito (1)
Satoru Motoyama (1)
Yusuke Sato (1)
Aki Ito (1)
Kei Yoshino (1)
Satoshi Kudo (1)
Shinogu Takashima (1)
Yasushi Kawaharada (1)
Nobuyasu Kurihara (1)
Kimito Orino (1)
Jun-ichi Ogawa (1)
1. Department of Chest (& Endocrinological) Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan - ISSN：1436-2813
文摘
Surgical resection is the accepted standard of care for patients with non-small cell lung cancer (NSCLC). Several imaging modalities play central roles in the detection and staging of the disease. The aim of this review is to evaluate the utility of computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and PET/CT for NSCLC staging. Radiographic staging refers to the use of CT as a non-invasive diagnostic technique. However, while the vast majority of patients undergo only CT, CT is a notoriously inaccurate means of tumor and nodal staging in many situations. PET/CT clearly improves the staging, particularly nodal staging, compared to CT or PET alone. In addition, as a result of the increased soft-tissue contrast, MRI is superior to CT for distinguishing between tissue characteristics. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), which is a minimally invasive technique, also has pathological diagnostic potential. Extensive research and the resultant improvements in the understanding of genetics, histology, molecular biology and oncology are transforming our understanding of lung cancer, and it is clear that imaging modalities such as CT, MRI, PET and PET/CT will have an important role in its preoperative management. However, thoracic surgeons should also be aware of the limitations of these techniques.